Screener Summaries Updates Institutions Sign In More Updates › Earnings › REPL Earnings · Jun 29, 2026
Replimune Group, Inc. issued a news release on June 29, 2026, announcing its financial results for the fourth fiscal… REPL Replimune Group, Inc.
Replimune Group, Inc. issued a news release on June 29, 2026, announcing its financial results for the fourth fiscal quarter and the full fiscal year ended March 31, 2026. The company provides corporate updates alongside its financial performance. Replimune Group, Inc. is a biotechnology company focused on developing oncolytic virotherapy products.
More from Replimune Group, Inc. Replimune reports $57.1M Q2 loss as TUDRIQEV launches for advanced melanoma Oct 28, 2026 Replimune Group, Inc. held its annual meeting of stockholders on September 15, 2026, where shareholders approved an… Sep 16, 2026 Replimune Group, Inc. announced the FDA accelerated approval of TUDRIQEV (vusolimogene oderparepvec-wtpg) in… Aug 14, 2026 Replimune Group, Inc. entered into an underwriting agreement to issue and sell 9,701,490 shares of common stock and… Aug 10, 2026 Replimune Group, Inc. priced an underwritten public offering of 9,701,490 shares of common stock at $12.06 per share… Aug 10, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
